Parkman Healthcare Partners LLC Syndax Pharmaceuticals Inc Transaction History

Parkman Healthcare Partners LLC

$687 Million
Q4 2024

A detailed history of Parkman Healthcare Partners LLC transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Parkman Healthcare Partners LLC holds 526,973 shares of SNDX stock, worth $8.63 Million. This represents 1.01% of its overall portfolio holdings.

Number of Shares

526,973

Previous 508,283 3.68%

Holding current value

$8.63 Million

Previous $9.78 Million 28.8%

% of portfolio

1.01%

Previous 1.38%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$12.52 - $21.81 $233,998 - $407,628	18,690 Added 3.68%	526,973 $6.97 Million
Q3 2024 Nov 14, 2024	SELL	$17.93 - $24.81 $1.66 Million - $2.29 Million	-92,415 Reduced 15.38%	508,283 $9.78 Million
Q2 2024 Aug 14, 2024	SELL	$18.82 - $23.79 $3.47 Million - $4.38 Million	-184,113 Reduced 23.46%	600,698 $12.3 Million
Q1 2024 May 15, 2024	BUY	$19.71 - $24.57 $911,035 - $1.14 Million	46,222 Added 6.26%	784,811 $18.7 Million
Q4 2023 Feb 14, 2024	BUY	$11.39 - $21.67 $5.99 Million - $11.4 Million	526,141 Added 247.66%	738,589 $16 Million
Q3 2023 Nov 14, 2023	BUY	$14.52 - $21.77 $60,722 - $91,042	4,182 Added 2.01%	212,448 $3.08 Million
Q2 2023 Aug 11, 2023	BUY	$19.35 - $22.31 $4.03 Million - $4.65 Million	208,266 New	208,266 $4.36 Million
Q1 2021 May 14, 2021	SELL	$19.28 - $24.59 $605,122 - $771,781	-31,386 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$15.1 - $26.44 $20,853 - $36,513	1,381 Added 4.6%	31,386 $698,000
Q3 2020 Nov 13, 2020	BUY	$13.39 - $17.48 $66 - $87	5 Added 0.02%	30,005 $443,000
Q2 2020 Aug 13, 2020	BUY	$8.94 - $20.98 $268,200 - $629,400	30,000 New	30,000 $445,000

Others Institutions Holding SNDX

# of Institutions

232

Shares Held

96.9M

Call Options Held

1.39M

Put Options Held

543K

View Full List

About Syndax Pharmaceuticals Inc

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $927M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

More about SNDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Parkman Healthcare Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parkman Healthcare Partners LLC with notifications on news.

Account

Parkman Healthcare Partners LLC Syndax Pharmaceuticals Inc Transaction History